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Abstract 
 
The use of drugs to improve animal growth is banned in the European Union. Nevertheless, 
illegal use has been demonstrated in several countries and Member States have to run 
extensive control programs to ensure that the ban is respected. The aim of this work was to 
explore the possibility of using surface plasmon resonance (SPR) biosensors to develop fast 
and robust screening assays for hormones and ß-agonists.  
Modified standard procedures for hapten synthesis were employed to immobilise stable 
analyte specific sensor chip surfaces used for analysis. Sensor chips for clenbuterol, 
ethinylestradiol and trenbolone gave assays with IC50 values in the region of 0.5 ng ml
-1. 
Sample matrix interference from urine and serum with the antibody-antigen interaction and 
non-specific binding from samples to the sensor surface was systematically studied. 
Strategies to minimise these effects were investigated and described.  
Biosensor assays for clenbuterol in bovine hair and urine, suitable for routine use, were 
developed and validated. For hair, a sandwich assay format was used. A rapid and simple 
extraction using 100 mM NaOH was developed, and the assay was validated by analysis of 
hair samples from animals treated with clenbuterol. The critical factor for assay sensitivity 
was non-specific binding to the sensor chip surface from hair extracts, which was controlled 
by ultrafiltration of samples and by the use of a secondary antibody. The LOD of the hair 
assay was 10 ng ml
-1.  
In the urine assay, the cross-reaction for several ß-agonists, including salbutamol, 
mabuterol and brombuterol was high, enabling detection of concentrations below 1 ng ml
-1. 
Analysis of these low analyte concentrations in urine without sample pre-treatment was 
limited by high sample-to-sample variation, inhibition of antibody binding to the surface 
and occasional non-specific binding. A rapid and simple sample clean-up using integrated 
immunofiltration was developed to minimise these sample matrix effects. With this method, 
at least 48 samples could be processed and analysed by one person in one working day. 
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Svensk populärvetenskaplig sammanfattning 
 
Inom EU är det förbjudet att använda hormoner eller andra ämnen med hormonell 
verkan, såsom beta-agonister, för att stimulera tillväxt hos djur i 
livsmedelsproduktion. Livsmedelsverket kontrollerar varje år både svenskt och 
importerat kött efter dessa ämnen. De senaste åren har kontrollen inom den 
svenska köttproduktionen omfattat drygt 1800 prover/år från slakterier och från 
levande djur på gård. Kontrollen av djur under uppväxtkedjan är ett komplement 
till kontrollen på slakterierna i syfte att kunna upptäcka illegal användning på ett 
så tidigt stadium som möjligt. På levande djur tas oftast urinprov, men det är också 
möjligt att testa blodprov eller hår. I urin går det i regel att hitta positiva prover 
under tiden djuret behandlas och under den påföljande veckan efter behandling.  
I hår lagras flera ämnen in, och det är möjligt att hitta rester av till exempel   
beta-agonister upp till flera månader efter behandling. 
 
Syftet med mitt doktorandarbete var att undersöka möjligheterna att använda en 
optisk biosensor för att utveckla snabba och säkra metoder för kontroll av illegal 
användning av hormoner och beta-agonister speciellt i urin och hår. I biosensorn 
använder man sig av antikroppar och ett chip med en guldyta, för att kunna mäta 
de ämnen man söker efter. Först modifieras guldchipets yta kemiskt, så att den blir 
specifik för ett visst ämne. När väl ytan är modifierad kan man sedan använda 
samma guldchip till flera hundra analyser.  
 
Under arbetets gång utvecklades specifika chipytor för tre olika hormoner: 
trenbolon, etinylöstradiol och hexestrol och två olika beta-agonister: klenbuterol 
och ractopamin. Chipen för klenbuterol, trenbolon och etinylöstradiol fungerade 
väl och kunde användas till att mäta låga halter, medan chipytorna för hexestrol 
och ractopamin behöver optimeras ytterligare. Ett av målen var att kunna 
analysera proverna direkt utan upprening, men det visade sig vara svårt eftersom 
olika ämnen från provet såsom proteiner och fett störde mätningen. Störningarna 
undersöktes, och en rad olika metoder att minska dem testades. 
 
Två snabba biosensormetoder för att analysera klenbuterol i hår respektive urin 
har utvecklats. Hårproverna extraherades först med natriumhydroxid för att lösa ut 
ämnet. För att bli av med störande ämnen som band in ospecifikt till chipytan 
krävdes det att hårextrakten filtrerades det genom ett ultrafilter innan analys. Med 
denna metod kan koncentrationer av klenbuterol i hår ner till 10 mikrogram per kg 
upptäckas. Antikroppen som användes till urinmetoden kunde förutom klenbuterol 
också fånga upp flera ämnen, bland annat salbutamol, mabuterol och brombuterol. 
Halter på 1 mikrogram per liter urin eller lägre av dessa beta-agonister kunde 
hittas. För att kunna finna så låga halter utvecklades en ny uppreningsmetod, där 
samma antikroppar används för upprening och analys i biosensorn. Med denna 
metod kan en person testa minst 48 prover under en arbetsdag. Biosensormetoden 
för urin används för närvarande i Livsmedelsverkets offentliga kontroll för analys 
av beta-agonister. 
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Introduction  
 
Growth promoters in meat production 
Anabolic steroids have been used in meat production since the 1950s. Initially the 
stilbenes, diethylstilbestrol (DES) and hexestrol were widely used but the 
seventies saw an increase in the use of 19-nortestosterone derivatives: trenbolone, 
zeranol and the three natural steroids: estradiol-17β, testosterone and progesterone 
(chemical structures in Figure 1).  A hormone scandal in 1980-1981 associated 
with illegal use of DES in veal calves started a chain of events, which lead to a 
European ban in 1988. The EU prohibited the use of all substances having a 
hormonal action for growth promotion in farm animals (Heitzman, 1993). Later  
ß-agonists were added to the list. This prohibition applies to Member States and 
imports from third countries alike. The legal instrument in force is Directive 
96/22/EC (EC, 1996a), as amended by Directive 2003/74/EC (EC, 2003).  
 
Trenbolone, zeranol, melengestrol acetate and the three natural hormones are 
legally used in several countries outside the EU, including USA and Canada, and 
the European ban led to a trade dispute. The Codex Alimentarus Commision Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) was involved to 
evaluate the safety risk related to the use of growth promoters. Risk evaluations 
have been summarised by Orr (1999) and the physiology of anabolic hormones 
used for meat production was reviewed by Meyer (2001). 
 
Illegal use has been demonstrated in several EU countries and Member States 
have to run extensive control programs to ensure that the ban is respected. The aim 
of this work was to explore the possibility to use surface plasmon resonance (SPR) 
biosensors, to develop fast and robust screening assays for growth promoting 
hormones and ß-agonists.  
 
  
 
Figure 1. The chemical structures of some anabolic steroids. 17ß-estradiol is the major 
natural estrogen, and hexestrol, diethylstilbestrol and zeranol are synthetic derivatives. 
Testosterone and progesterone are natural androgens, while trenbolone is derived from   
19-nortestosterone. 
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The ß-agonists 
ß2-agonists are a class of compounds derived from naturally occurring 
catecholamines (adrenaline, noradrenaline and dopamine). In human medicine 
they are extensively used for chronic obstructive airway diseases, such as asthma 
and bronchitis (Witkamp, 1996). For veterinary therapeutics, the use of ß-agonists 
has only been approved in the case of clenbuterol for bronchodilatation in horses 
and calves, and for tocolysis in cows (Kuiper et al., 1998). For growth promoting 
purposes, ß-agonists are banned in the European Union under Council Directive 
96/22/EC (EC, 1996a). With respect to the therapeutic use, a maximum residue 
limit (MRL) of 0.5 µg kg
-1 was established for clenbuterol in bovine and equidae 
liver (EC, 2000).  
 
ß-agonists act through their binding to ß-receptors located on various cell types, 
including neuronal and muscle cells, fat cells and blood cells. To date, 3 types of 
ß-receptors have been classified, ß1, ß2 and ß3 (e.g. Witkamp, 1996). The effects 
of ß2-receptor stimulation include increased heart rate, dilation of coronary 
vessels, relaxation of bronchial and uterine muscle tone and stimulation of insulin 
release and glycogenolysis. ß-agonists have proven to be efficient repartitioning 
agents, promoting reduction in body fat and muscle growth in cattle (Ricks et al., 
1984), poultry (Dalrymple et al., 1984), swine (Jones et al., 1985) and sheep 
(Baker  et al., 1984; Beermann et al., 1987). To achieve these effects, it is 
necessary to use doses 5-10 times higher than common therapeutic doses (Miller et 
al., 1988). During the last 15 years, illegal use of ß-agonists for growth promoting 
purposes, have been reported in Europe and USA (Kuiper et al., 1998; Mitchell & 
Dunnavan, 1998). Pharmacological aspects of clenbuterol in growth promotion 
and methods of analysis were further reviewed by Prezelj, Obreza & Pecar (2003). 
 
The unwanted side effects of ß-agonists are predictable extensions of their 
pharmacological action: tachycardia, muscle tremor, palpitation, peripheral 
vasodilatation, nervousness and metabolic effects (Witkamp, 1996). In a series of 
acute food poisoning outbreaks in the nineties, a large number of patients were 
diagnosed according to these symptoms after consumption of bovine liver and 
meat containing high levels of clenbuterol. In Spain, 367 cases in two major 
outbreaks were reported (Martinez-Navarro, 1990 and Salleras et al., 1995). In 
France, 22 patients developed clinical symptoms associated with consumption of 
contaminated veal liver (Pulce et al., 1991), and in Italy consumption of fillet and 
rump steaks containing clenbuterol concentrations above 0.5 ppm lead to food 
poisoning of 16 persons (Maistro et al., 1995). 
 
Chemical properties and metabolism in food-producing species 
For a ß-agonist to have biological activity it must have a substituted six-membered 
aromatic ring, hydroxyl group bonded to the ß-carbon in the R configuration, 
positively charged nitrogen in the ethylamine side chain and bulky substituent (R 
in Figure 2) on the aliphatic nitrogen. The chemical substitutents on the aromatic 
ring greatly influence the longevity of the ß-agonist within the mammalian tissue 
and the compound’s efficacy at the receptor (Smith, 1998). Ring hydroxylated  
ß-agonists, such as salbutamol and ractopamine are rapidly deactivated by   13
enzymes in the liver and intestine, while halogen substituted ß-agonists withstand 
these enzymes. The halogens do not however inhibit binding to the receptor. 
Mabuterol and clenbuterol were designed specifically to resist rapid metabolic 
degradation by enzymes active toward aromatic hydroxyl groups (Morgan, 1990). 
 
The metabolic pathways of biotransformation for ring hydroxylated ß-agonists 
such as salbutamol and ractopamine, works exclusively through conjugation with 
sulphate or glucuronic acid in all species investigated. Conjugation of the aromatic 
hydroxyl group is the only confirmed site for these types of ß-agonists (Smith, 
1998). The major metabolite excreted in bovine urine after clenbuterol treatment 
was an oxidation product of the primary amine function of CBL,   
CBL-arylhydroxylamine. It accounted for approximately 40% of the excreted 
compound, while 40% of the excreted compound was reported to be in the 
parental form (Zalco, Bories & Tulliez, 1996; Zalco et al., 1998). 
 
Clenbuterol accumulates to various degrees in different tissues like blood, urine, 
muscle, liver and eye (Sauer et al., 1995). In blood serum, clenbuterol 
concentrations peaked at 1.1 ng ml
-1 within 5 hours after treatment on day 21 of 
treatment. Within 24 hours of withdrawal, plasma concentrations were below 0.4 
ng ml
-1. In urine, the highest concentration was 193 ng ml
-1, and concentrations 
above 0.5 ng ml
-1 were detected up to 5 days after withdrawal. In liver, 
concentrations above 0.5 ng ml
-1 were detected on day 14 after withdrawal, while 
concentrations in the eye were approximately 30 times higher (Meyer & Rinke, 
1991). Similar results were shown in sheep (Elliott, McCaughey & Shortt, 1993). 
 
 
 
Figure 2. Chemical structure of ß-agonists a) the general structure, b) examples of   
ring-hydroxylated ß-agonists: salbutamol and ractopamine, and c) examples of halogen 
substituted ß-agonists: clenbuterol, mabuterol and brombuterol. 
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Another site for accumulation of clenbuterol residues is pigmented hair (Dürsch, 
Meyer & Karg, 1995; Appelgren et al. 1996). According to Gaillard et al. (1997) 
hair testing was effective after 7-10 days of treatment, while Gleixner, Sauerwein 
& Meyer (1996) detected clenbuterol residues in hair samples from day 4 to day 
60 of their experiment. Hair analysis has proven to be a good complement to the 
conventional urine analysis due to the long retention time of the drug and easy 
sampling compared to other matrices. Since excretion of clenbuterol in urine is 
faster, but only present for a shorter period, a combination of urine and hair 
analysis is a possible approach to maximise the chance of detecting illegal use of 
drugs in meat-producing animals. 
 
Analytical strategies and methods 
Council Directive 96/23/EC (EC, 1996b) requires all European Union (EU) 
Member States to monitor residues of a range of licensed and illegal compounds in 
live animals and animal products, to provide assurance to the consumer on the 
quality and safety of food. Many EU member states have established a two step 
approach for drug monitoring, which comprises of a screening test followed by, if 
required, a confirmatory analysis (Elliott et al., 1998a; Kuiper et al., 1998). 
Confirmatory analysis of ß-agonists is based on GC-MS (e.g. Blanchflower et al., 
1993; van Ginkel, Stephany & van Rossum, 1992) or LC-MS (e.g. De Wasch, De 
Brabander, & Courtheyn, 1998).  
 
For screening purposes, immunochemical methods are generally used. 
Yamamoto & Iwata (1982) reported the first competitive enzyme immunoassay 
(EIA) for clenbuterol. Several methods for urine (e.g. Degand, Bernes-Duykaerts 
& Maghuin-Rogister, 1992; Elliott et al., 1993; Haasnoot et al., 1996) and hair  
(e.g. Gleixner, Sauerwein & Meyer, 1996; Godfrey et al., 1996; Haasnoot et al., 
1998) have been published, and various EIA-kits are commercially available. 
Radioimmunoassay procedures (RIA) have also been developed for the detection 
of clenbuterol in extracts from a range of samples (Delahaut et al., 1991; Boyd, 
O'Keeffe & Smyth, 1994). A more recent detection technique is immunobiosensor 
analysis. SPR-biosensor methods for liver (Traynor et al., 2003) and urine 
(Haughey et al., 2001) have been developed.  
 
Sample clean-up methods for hair generally include an overnight alkaline 
digestion at elevated temperature, combined with liquid-liquid extraction with   
tert-butyl methyl ether or solid-phase extraction. In some methods the dissolving 
agent DTT (1,4-dithiothreitol) was used to break disulfide bonds to release tightly 
bound clenbuterol (Gleixner, Sauerwein & Meyer, 1996; Godfrey et al., 1996; 
Sauer & Anderson, 1994). The extracts produced were complex and required 
further purification. Faster sample clean-up was obtained with mild extraction 
using 200 mM carbonate buffer pH 10 (Elliott Crooks & McCaughey, 1995) and a 
digestion-extraction using tert-butyl methyl ether (Haasnoot et al. 1998).  
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The optimal screening assay should be fast and should not require any sample 
clean-up, but direct analysis of ß-agonists in bovine urine has proven to be 
difficult due to a large sample-to-sample variation. Hahnau and Jülicher (1996) 
stated that none of the nine commercial ß-agonist-EIA kits on the market was 
sensitive enough for residue control analysis of urine without a previous clean-up.  
Today, most immunochemical screening methods are used in combination with 
liquid-liquid extraction (LLE), solid phase extraction (SPE) or immunoaffinity 
chromatography (IAC) (Nausch & Galley, 1997). Since salbutamol is 
predominantly excreted as a sulphate conjugate, enzymatic deconjugation may be 
required prior to sample clean-up, in order to fully recover the analyte. Sample  
pre-treatment and sample clean-up methods for ß-agonists in biological matrices 
were further reviewed by Boyd, O’Keefe & Smyth (1996).  
 
Collins, O’Keeffe & Smyth (1994) used mixed mode SPE columns in 
combination with a radioimmunoassay (RIA) to analyse four different ß-agonists 
in urine, achieving a limit of detection (LOD) of 0.13 ng ml
-1. Iso-butanol was 
used by Haasnoot et al. (1996) to extract several ß-agonists, including both 
clenbuterol and salbutamol (SBL), to achieve LODs below 1 ng ml
-1 for their ß-
agonist EIA. In the biosensor method by Haughey et al. (2001), urine samples 
were extracted with tert-butyl methyl ether (TBME) and concentrated eightfold, 
resulting in a LOD of 0.27 ng ml
-1. This method was, however, not able to extract 
SBL and other phenolic ß-agonists. The commercial Biacore kit based on the 
method was reported to be somewhat slower than ELISA, but had a lower false 
positive rate at the 0.3 ng ml
-1 level, when tested on-line at a slaughter house 
(Guggisberg, Widmer & Koch, 2001). 
 
A new approach for sample clean-up is immunofiltration (IF), which was 
employed in combination with a ß-agonist EIA by Haasnoot et al. (2001). The 
urine sample was mixed with antibodies in an ultra-filtration (UF) device. After 
centrifugation, the bound CBL was released from the antibodies with a mixture of 
methanol and acetic acid. The eluate was evaporated, dissolved in PBS-buffer and 
analysed with EIA, resulting in lower numbers of false positive samples compared 
to iso-butanol clean-up.   16
Biosensors in food analysis   
A biosensor is an analytical device that combines the specificity of a biological 
interaction with a transducer that produces a signal proportional to the target 
analyte concentration (Mulchandani & Bassi, 1995). The biological recognition 
element (e.g. antibodies, enzymes, receptors and microbial cells) is in close 
contact with a signal transducer (e.g. optical, amperometric, potentiometric and 
acoustic) coupled to a data acquisition and processing system (Patel, 2002). An 
overview of the operating principles of a biosensor is shown in Figure 3. 
 
Different types of biosensors and their application in food safety were recently 
reviewed (Patel, 2002; Velasco-Garcia & Mottram, 2003; Leonard et al., 2003). 
Amperometric devices are the most commonly reported class of biosensors. 
Detection typically relies on an enzyme system that catalytically converts the 
analyte to a product, which can be oxidised or reduced at a working electrode 
maintained at a specific potential. The most commercially important application is 
the hand-held glucose meter used by diabetics (Velasco-Garcia & Mottram, 2003). 
A wide range of enzyme biosensors for applications in food analysis have been 
described, e.g. for detection of glucose, carbohydrates, ethanol, starch and phenols 
(Mello & Kubota, 2002). In contaminant analysis, enzyme biosensors have largely 
been used for organophosphorus and carbamate pesticide and herbicide analysis. 
Assays for penicillin G and V have also been reported (Patel, 2002).   
 
Another class of biosensors is affinity-based sensors. They typically use the 
interaction antibody-antigen, receptor-ligand or protein-nucleic acid. Upon 
interaction, the physical properties at the sensor surface, e.g. refractive index, 
mass, density or thickness is affected (Kress-Rogers, 1997). The change can be 
monitored in real time using acoustic (piezoelectric) materials or optical   
(e.g. surface plasmon resonance, SPR or resonant mirror) transducers (Bilitewski, 
2000). One of the advantages of optical transduction is that, whatever the 
biorecognition chemistry, the outcome can be followed in a non-destructive 
manner (Pearson, Gill & Vadgama, 2000).  
 
 
 
Figure 3. Schematic diagram of the main components of a biosensor. The biological event, 
e.g. antibody-antigen interaction elicits a physico-chemical change at the biointerface, e.g. 
change of mass, heat or in electrical potential, which is converted by the transducer to an 
electrical signal. The output is amplified, processed and displayed as a measurable signal. 
   17
  
 
Biacore AB, formerly Pharmacia Biosensor AB, was the first company to 
commercially develop SPR-technology in 1990 (Liedberg Nylander & Lundström, 
1995). During the last few years, Biacore technology has been used in 
approximately 90% of all work published in the optical biosensor field (Myszka, 
1999, Rich and Myszka, 2000a; 2001; 2002). Other commercially available   
SPR-systems include IAsys from Affinity Sensors, Spreeta from Texas 
instruments and Nippon Laser and Electronics systems (Baird & Myszka, 2001; 
Mullett, Lai & Yeung, 2000; Leonard et al., 2003).  
 
The main applications of Biacore systems are for the determination of affinity 
and kinetics of interaction between two or more biomolecules (Karlsson & Fält, 
1997; Myszka, 1997), receptor-ligand interactions (Cunningham & Wells, 1993) 
and nucleic acid hybridisation (Persson et al. 1997). The systems have also been 
used for quantitative analysis using antibodies as specific reagents (Mellgren & 
Sternesjö, 1998) and for the thermodynamic analysis of biomolecular interactions 
(Roos  et al., 1998). Only a minor part of the applications published so far is 
related to food analysis or food safety. 
 
In the current work, two similar models (Biacore 2000 and Biacore Q) of optical 
SPR-biosensors were used to detect residues of veterinary drugs. Since antibodies 
were used for biological recognition in these particular applications, the biosensors 
were referred to as immunosensors or immunobiosensors (Marco, Gee & 
Hammock, 1995).  
 
Biacore analysis 
The main components of the Biacore system are the interchangeable sensor chip, 
the microfluidic sample handling system and the surface plasmon resonance (SPR) 
detector. Aqueous samples are serially injected over the sensor chip surface 
immobilised with one of the interacting partners. Binding of the interactant is 
detected and quantified in real-time by the surface sensitive detector (Löfås, 
1995).  
 
Optical system 
In principle, the SPR-immunosensor measures the mass concentration change   
caused by binding of an antibody (or analyte) to the corresponding analyte   
(or antibody) immobilised on the sensor surface (Patel, 2002). The SPR 
phenomenon occurs when plan polarised light is reflected from a gold film 
deposited on a glass support (Liedberg, Nylander & Lundström, 1983). Photons 
react with the free electron cloud in the metal film at a specific angle, the SPR-
angle, and cause a drop in the reflected light. Refractive index changes near the 
surface give rise to a shift of the resonance angle. The shift is directly proportional 
to the mass increase and mass concentration can thus be measured (Stenberg et al., 
1991). The analysis principle is summarised in Figure 4.  
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The response from angular shift is expressed in resonance units (RU) and 1 RU 
corresponds to shift of 0.0001° (Jönsson et al. 1991). By plotting the angular shifts 
against time a sensorgram, describing the interaction at the surface in real time, is 
obtained (Figure 5). 
 
 
 
 
 
Figure 4. Surface plasmon resonance (SPR) biosensor principle. Binding of biomolecules to 
the surface increase the refractive index, which induces shift of the SPR-angle. The shift is 
directly proportional to the mass increase.  
 
 
 
 
 
 
 
Figure 5. A sensorgram illustrating the interaction between free antibody in sample and 
antigen immobilised on the surface. The different phases are recorded in real time 
including, (a) baseline equilibrium (continuous buffer flow), (b) binding of antibody to the 
sensor surface during sample injection, (c) response after sample injection, (d) regeneration 
of the sensor surface and (e) baseline stabilisation.  
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Figure 6. The surface of a sensor chip consists of three layers; glass, a thin gold film and a 
dextran layer, to which biomolecules can be immobilised.  
 
Sensor surface 
The sensor chip consists of a gold-coated glass slide embedded in a plastic support 
platform (Figure 6). The gold film is covered with a covalently bound dextran 
layer to which biomolecules can be immobilised. Different types of sensor 
surfaces are available, but the most frequently used surface is carboxymethylated 
dextran, CM5 (Rich & Myszka, 2000b). The SPR-technique is sensitive to 
refractive index changes to a distance of approximately 1 µm out into the solution, 
and the dextran matrix increases the binding capacity of the surface, as it extends 
out approximately 100 nm in water solutions. In addition, the non-specific binding 
from proteins compared to a bare gold surface is minimised (Liedberg, Lundström 
& Stenberg, 1993). 
 
Flow system 
When a sensor chip is docked in the instrument, the integrated µ-fluidic cartridge 
(IFC) is pressed against the chip surface (Sjölander & Urbaniczky, 1991). The IFC 
forms three flow cell walls, while the sensor chip forms the fourth wall. There are 
four flow cells that can be fed and monitored separately. Flow cell volumes range 
from 20-60 nl depending on instrument model (Baird and Myszka, 2001). The 
sensor surface is exposed to a constant analyte concentration by a continuous flow 
of buffer sample injections, controlled by an autoinjector in combination with the 
IFC. Generally, sample volumes of 5-450 µl at flow rates of 1-100 µl min
-1 can be 
injected. For some models (e.g. Biacore 2000 and 3000), a sample can be passed 
over the four flow cells in sequence and the response for all flow cells can be 
monitored in parallel, while for other models (e.g. Biacore 1000 and Biacore Q) 
only one flow cell can be monitored at the time. 
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Figure 7. In the inhibition assay format the analyte itself is often immobilised to the 
surface. A mixture of sample and antibody is injected, and the antibody binding is 
measured. 
 
Inhibition assay 
The sensitivity of direct analysis in current instruments is insufficient for 
determining low levels of low-molecular-weight analytes such as antibiotics, 
hormones and residues. Instead, an inhibition assay format is used, in which the 
analyte or analyte conjugate is immobilised on the surface (Bilitewski, 2000). 
Antibodies are added to the sample prior to injection (Figure 7). If the analyte is 
present, binding will occur, and some antibodies will be blocked. The mixture is 
injected over the surface, and the concentration of antibody free to bind to the 
sensor surface is measured. At a high analyte concentration most antibodies will 
be inhibited, resulting in a low response, while a blank sample will give a high 
response. Thus, in the inhibition assay format the SPR change is inversely 
proportional to the analyte concentration in the sample. 
 
Assay development 
Immobilisation of analyte specific chip surface 
The most generally applicable immobilisation strategy is amine coupling, where 
the ligand is coupled via primary amino groups. Alternative strategies include 
coupling via thiol or aldehyde groups of the biomolecule, or using 
streptavidin/biotin interaction (Löfås et al., 1995). Amine coupling introduces   
N-hydroxysuccinimide esters into the surface matrix by modification of the 
carboxymethyl groups with a mixture of N-hydroxysuccinimide (NHS) and   
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). These 
esters then react spontaneously with amines and other nucleophilic groups on the 
ligand to form covalent links (Johnsson, Löfås & Lindquist, 1991; O'Shannessy, 
Brigham-Burke & Peck, 1992). Non-reacted active esters are deactivated by 
addition of ethanolamine hydrochloride. Amine coupling is shown in Figure 8. 
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Figure 8. Amine coupling of ligand to a sensor surface: a) Non-activated carboxylic groups 
on the dextran; b) The carboxylic groups are activated by addition of a mixture of 
succinimide (NHS) and carbodiimide (EDC); c) The ligand is covalently bound to the   
sensor surface; d) Remaining esters are deactivated by addition of ethanolamine (Johnsson, 
Löfås & Lindquist, 1991). For some analytes the surface is amino modified by addition of 
ethylenediamine prior to immobilisation. 
 
The number of ligand molecules that will be immobilised is affected by the 
number of NHS/EDC activated carboxymethyl groups, the pH, the ionic strength 
and the concentration of the coupling buffer, and by ligand concentration and 
reaction times. For proteins, different coupling buffers can be tested prior to 
immobilisation by injecting ligand over a non-activated surface, without affecting 
the surface. The process is called pre-concentration and is monitored in a 
sensorgram. Pre-concentration is however not possible with small ligands due to 
mass sensitivity limitations of the instrument (Löfås et al. 1995). 
 
Surface regeneration 
The vast majority of biosensor methods need regeneration of the sensor surface 
before measurement can be repeated. An ideal regeneration solution should 
completely remove all non-covalently bound material from the surface, while 
maintaining the activity of the ligand. A common approach for antibody-antigen 
regeneration is to use agents with high or low pH, i.e. NaOH, HCl or glycine 
(Andersson, Hämäläinen & Malmqvist, 1999). A combination of different agents 
is however more efficient for breaking “stronger” interactions between antibodies 
and antigens. Dissociation is promoted by a combination of a strong electron-
donor organic solvent (e.g. dimethylsulfoxide, ethylene glycol or propanol) with 
an increase or decrease of pH (van Oss, 1994). Addition of chaotropic salts,   
e.g. guanidine hydrochloride, ionic detergents, e.g. SDS (sodium dodecyl 
sulphate) and addition of acetonitrile are other options (Tsang & Wilkins, 1991; 
Newman, Olabiran & Price, 1997). The binding forces involved in the antibody-
antigen interaction and optimal conditions for dissociation are well described 
elsewhere (Jefferis & Deverill, 1991; van Oss, Good & Chaudhury, 1986). In 
order to facilitate assay development and enable standardised regeneration, a 
general capturing surface was used in some Biacore applications (Bergström et al., 
1999; Gustavsson et al., 2002).  
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Reduction of sample matrix effects 
In an inhibition assay there are two main types of sample matrix effects present, as 
shown in Figure 9. First sample matrix components can bind non-specifically to 
the surface. Secondly, the interaction between antibody and analyte in solution, or 
analyte liganded to the surface, can be hindered by matrix components.   
Non-specific binding to the surface (NSB), which is usually caused by larger 
components such as proteins and fat aggregates, may add to the specific response 
(SB) and increase the risk of false negative results (c). If the initial interaction 
between antibody and antigen in the pre-injection mixture is disturbed by matrix 
components (a), the assay sensitivity in the sample matrix as compared to the 
buffer is decreased. Hindrance of the interaction between antibody and surface 
ligand (b) reduces the SB in matrix compared to buffer. 
 
The most frequently discussed matrix effect in biosensor analysis of food is non-
specific binding. A common approach to reduce NSB is to use sample dilutions of 
10 times or more (Baxter et al., 1999, Johnsson et al., 2002; Haasnoot, 
Bienenmann-Ploum & Kohen, 2003). In a folate-binding protein assay, a wash 
step was introduced after sample injection, to reduce the impact of NSB from  
rennet-treated milk (Nygren, Sternesjö & Björck, 2003), while a reference flow 
cell, immobilised with rabbit IgG, was used to correct for NSB in an assay for 
non-milk proteins in milk powder (Haasnoot et al., 2001).  Bovine serum proteins 
were precipitated with saturated ammonium sulphate prior to biosensor analysis of 
benzimidazole residues (Johnsson et al. 2002). Addition of dextran to the assay 
buffer has also been used (Bergström, 1998). 
 
 
 
Figure 9. Sample matrix effects in a biosensor inhibition assay. Matrix components can 
interfere with the antibody-antigen interaction in the pre-biosensor mixture (a), adhere to 
the antibody or the surface ligand and thereby hinder the antibody to bind to the surface (b), 
and bind non-specifically (NSB) to the surface (c). 
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Calibration curves spiked in sample matrix (Gaudin & Maris, 2001; Bjurling et al., 
2001; Ferguson et al., 2002) have been used to compensate for the matrix 
inhibition effect. Haughey et al. (2001) prepared a calibration curve in phosphate 
buffer with addition of urea and creatinine to mimic the main components in urine. 
The matrix inhibition effect from liver extracts was substantially reduced by 
delaying the mixing of antibody and sample until just prior to sample injection 
(Traynor et al., 2003). Standard sample clean-up such as liquid/liquid extraction or 
solid phase extraction has also been used in several assays (Haughey et al., 2001; 
Traynor et al., 2003; Ferguson et al., 2002). 
 
Signal enhancement  
The detection sensitivity can be amplified with a second molecule (ligand or 
antibody) that binds to the analyte in a sandwich assay (Mullett, Lai & Yeung, 
2000). Secondary antibodies were used to increase the response and to reduce the 
impact of non-specific binding (e.g. Jonsson, Malmheden-Yman & Hellenäs, 
2001). Sub-micron latex particles were shown to improve the sensitivity of an 
SPR-immunoassay for human chorionic gonadotropin by a factor 30 (Severs & 
Schasfoort, 1993). In another study, Kubitschko et al. (1997) optimised a 
nanoparticle-enhanced immunoassay, with respect to particle size, coating 
conditions and non-specific binding of nanoparticles.  
 
Biacore assays in food analysis 
For food borne pathogens and their toxins, a number of assays based on the 
Biacore technique have been developed over the last decade. Fratamico et al. 
(1998) developed an assay for detection of Escherichia coli O157:H7 and 
inhibition of binding of the bacteria to extracellular matrix components was 
studied by Medina (2001 & 2002). Staphylococcal enterotoxin B was detected 
(Rasooly, 2001; Medina, 2003) and Nedelkov & Nelson (2003) combined a 
Biacore assay with MALDI-TOF MS to quantify the toxin. Serum antibodies 
against two types of Salmonella in chicken were detected in parallel with a 
Biacore 3000 assay developed by Jongerius-Gortemaker et al. (2002). Assays for 
whole cells of Listeria monocytogenes (Leonard et al. 2004) and Salmonella cells 
group B, D and E (Bokken et al. 2003) were also developed. Other applications in 
the food safety area were analysis of the fungal aflatoxin B(1) by Daly, et al., 
(2000) and allergen detection in different food matrices (Jonsson, Malmheden-
Yman & Hellenäs, 2001). Insulin-like growth factor 1 (IGF-1) was analysed to 
detect the use of recombinant bovine somatotropin (rBST), which is used to 
increase the milk yield from cows (Guidi et al., 2001). The detection of pesticides 
(Minunni, & Mascini, 1993; Alcocer et al., 2000) has also been addressed, and 
genetically modified organisms (GMO) were analysed using DNA hybridisation 
(Mariotti, Minunni, & Mascini, 2002). Feriotto et al. (2002; 2003) developed 
methods for Roundup Ready soybean gene sequences and quantitative 
determination of transgenic maize.  
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A number of assays have been developed for components in bovine milk, e.g. 
detection of non-milk proteins in milk powder (Haasnoot et al., 2001), 
determination of folate binding protein (Nygren, Sternesjö & Björck, 2003) and 
analysis of progesterone in bovine milk to predict cows’ pregnancy (Gillis et al., 
2002). Casein was measured in milk and ripening cheese (Muller-Renaud, Dupont, 
& Dulieu, 2004) and immunoglobulin G in bovine colostrum and milk (Indyk & 
Filonzi, 2003). Biacore assays were also developed for water-soluble vitamins e.g. 
folic acid, biotin, vitamin B12 and riboflavin in fortified food, infant formula and 
milk (Boström Caselunghe & Lindeberg 2000; Indyk et al., 2002; Indyk et al., 
2000; Caelen, Kalman, & Wahlström, 2004).  
 
Biacore assays for veterinary drug residues in food 
In drug residue analysis too, the majority of the Biacore applications were 
developed for milk, e.g. sulfamethazine, enrofloxacin/ciprofloxacin, streptomycin 
and ivermectin (Sternesjö, Mellgren & Björck 1995; 1998; Baxter et al., 2001; 
Samsonova et al., 2002a). An inhibition assay format, with addition of antibodies 
to the sample prior to injection, was used in most cases (e.g. Gaudin & Pavy, 
2000; Ferguson et al., 2002; Johnsson et al., 2002; Samsonova et al., 2002b) with 
a few exceptions. Gentamicin (Haasnoot & Verheijen, 2001) and streptomycins 
(Haasnoot et al. 2002) were detected in direct assays, i.e. samples were injected 
over a sensor surface immobilised with antibodies and binding of analyte was 
measured directly. Direct assays for these small molecules (MW < 1000 D) were 
enabled by a higher sensitivity of the optical system in combination with a smaller 
flow cell and the online data subtraction feature in the Biacore 3000 system 
compared to earlier models (Rich & Myszka, 2000b).  
 
Most residue applications were developed for veterinary drugs with maximum 
residue limits (MRL) ranging from 4 ng ml
-1 for penicillin G in milk (Gaudin, 
Fontaine & Maris, 2001) to 100 and 200 µg kg
-1 for levamisole in liver and 
nicarbazin in chicken respectively (Crooks et al., 2003; McCarney et al., 2003). 
Assays for detection of concentrations at or below 1 ng ml
-1 were developed for 
clenbuterol in urine (Haughey et al., 2001), ß-agonists in liver (Traynor et al., 
2003) and chloramphenicol in milk (Gaudin & Maris, 2001). These low detection 
limits all required some sort of sample preparation. Concentrations of ractopamine 
analysed in urine without sample pre-treatment were somewhat higher (Shelver & 
Smith, 2003). Two direct assays were discussed earlier (Haasnoot & Verheijen, 
2001; Haasnoot et al. 2002.) Both assays had IC50 values of 20 ng ml
-1 in buffer 
and a dynamic range of approximately 100 RU, which indicate that present 
instrumentation does not enable direct detection of concentrations below 1 ng ml
-1. 
 
High sample throughput is another feature of the Biacore system, as was 
demonstrated for sulfamethazine (Elliott et al., 1999) and sulfadiazine (Crooks et 
al., 1999) in pigs’ bile. Furthermore, the robustness of the Biacore instrumentation 
was demonstrated by on-site application in a pig abattoir (Baxter et al., 1999). 
Simultaneous analysis of several samples, or for several analytes in one sample, 
was demonstrated in the EU-project FoodSENSE (FAIR-CT98-3630), using a 
prototype system with 8 parallel flow cells (Crooks et al., 2001). The system was 
successfully used for on-line detection of sulfamethazine and sulfadiazine in   25
porcine bile and the analysis time for one 96-well plate was shortened from 540 to 
50 minutes using the prototype, compared to analysis using a commercial Biacore 
1000 (Situ et al., 2002). 
 
Analysis of several groups of drug residues in parallel is the ultimate goal, 
which require the possibility of immobilising one analyte in each flow cell without 
contaminating the instrument. For Biacore systems, this has been facilitated by an 
external immobilisation station (surface preparation unit). Instruments that allow 
simultaneous detection in four flow cells are available (i.e. the Biacore 2000 and 
3000 models). Applicability was demonstrated in an inhibition assay with parallel 
detection of five different aminoglycosides, immobilised in different flow cells, 
and simultaneously analysed with a mixture of antibodies (Haasnoot et al., 2003). 
Recently, an automated micro array system using multi-analyte immunoassays 
with an indirect competitive ELISA format for simultaneous detection of 10 
different antibiotics in milk was reported (Knecht et al., 2004). Another possibility 
to analyse several compounds, is to use a receptor protein, which was 
demonstrated in two Biacore sensor assays for ß-lactams in milk (Gustavsson et 
al. 2002; Gustavsson, Bjurling, & Sternesjö, 2002; Gustavsson, 2003). The latter 
assay was based on the enzymatic activity of the receptor protein, which was 
inhibited in the presence of ß-lactams.    26
Objectives 
 
The overall aim of this study was to investigate the applicability of optical 
biosensors to screening for low levels of residues of illegal growth promoting 
drugs in foods and tissues from food producing animals, and to develop fast and 
reliable screening tests with a minimum of sample pre-treatment. 
 
Specific objectives for this work were:  
 
•  To prepare stable analyte specific surfaces for ß-agonists and hormones 
and to establish optimised assay conditions for binding and regeneration 
of antibodies. 
 
•  To investigate strategies to minimise sample matrix effects through 
optimisation of assay conditions. 
 
•  To develop and validate an immunobiosensor assay for screening of 
clenbuterol residues in bovine hair. 
 
•  To develop and validate a fast immunobiosensor assay for screening of 
residues of clenbuterol and salbutamol type of ß-agonists, below   
1 ng ml
-1 in urine. 
 
 
   27
Materials and methods  
 
Immobilisation  
Immobilisation of analyte-specific chip surfaces with clenbuterol, ractopamine, 
hexestrol, trenbolone and ethinylestradiol are described in detail in paper I.   
All immobilisations were performed in a moist chamber on an ELISA plate shaker 
outside the instrument, by applying 75 µl of each reagent solutions to the chip 
surface. The chip surface was rinsed with deionised water between each reagent. 
Reaction times ranged from 1 to 24 hours.  
 
Amine coupling, as described earlier, was used for all immobilisations. The free 
primary amino groups of ractopamine and hexestrol derivatives were allowed to 
react directly with the activated chip surface, while the chip surface was 
covalently modified to carry amino groups, prior to immobilisation of clenbuterol, 
trenbolone and ethinylestradiol. The remaining unreacted active ester groups on 
the surface were deactivated by addition of ethanolamine. Chemical structures for 
the analytes and reagents used for immobilisation are shown in Figure 10. 
  
The immobilisation procedures for ractopamine (RCP) and hexestrol (HEX) 
were derived from a method for the coupling of fenoterol to a carrier protein 
(Lommen, Haasnoot & Weseman 1995). One of the phenolic groups of RCP or 
HEX readily reacted with one of the two epoxy-groups of bisoxirane (BIS) under 
alkaline conditions, forming stable ether bonds. The remaining epoxy-group of 
BIS was allowed to react with ammonia to form a primary amino group free to 
react with the activated carboxylic groups on the sensor chip surface.   
 
Thiophosgene was used to convert the primary aromatic amine group of 
clenbuterol to the corresponding isothiocyanate. The reaction was performed 
under neutral conditions and the formed isothiocyanate was allowed to react with 
an amino-modified surface at pH 10.  
 
Trenbolone was converted to the corresponding succinimidyl carbonate under 
anhydrous conditions in a DMAP (4-dimethylaminopyridine) catalysed reaction 
between the hydroxyl group of trenbolone and DSC (N,N-disuccinimidyl 
carbonate) in a modification of the procedure used by Miron & Wilchek (1993). 
The product was allowed to react with the amino-modified surface for 1 hour 
forming a carbamate. 
 
Ethinylestradiol-carboxy-methyloxime (EEO-CMO) in dimethylformamide 
(DMF) was mixed with EDC and NHS in 10 mM sodium acetate pH 4.6. The 
product was allowed to react with the amino-modified surface. This chip surface 
was a gift from Veterinary Science Division, Belfast, UK. 
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Figure 10. Chemical structures of analytes (a) and their corresponding reagents (b) used for 
immobilisation. Primary reaction sites are indicated by arrows. 
 
 
Assay setup and optimisation 
Unless otherwise stated, the assay buffer used was 10 mM HEPES pH 8.2 with  
0.5 M NaCl, 3.4 mM EDTA and 0.005% P20. All primary antibodies were first 
diluted in a double strength assay buffer and then mixed (1+1) with samples and 
standards prior to analysis. Since samples were typically prepared batch by batch, 
and injected in a sequence, the incubation time could range from minutes to hours 
with no detectable difference in the result. Assays were typically run at a 
continuous flow of 30 µl min
-1, sample injection times were two minutes and 
regeneration solutions were injected in one or two pulses of 30 seconds each.  
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Antibodies 
The primary antibody preparations used in the present work are summarised in 
Table 1. All antibody reagents used were dilutions of serum or ascites fluid 
without further purification. Concentrations of antibodies directed against a 
specific analyte in serum or ascites were measured as the active antibody 
concentration (Rmax) according to Karlsson et al. (1993) as further discussed in 
paper I. A secondary antibody (affinity purified goat anti-rabbit) was used for 
signal enhancement in analysis of clenbuterol in hair (see paper III). 
 
Table 1. Overview of primary antibody preparations used in the present work and the 
coupling chemistry of the immunogen during the production of the antibodies. All these 
antibodies were gifts from VSD in Belfast (C. T. Elliott), TNO in Zeist (C. Arts) or RIKILT 
in Wageningen (W. Haasnoot).  
 
        
Antibody   Type
a  Hapten   Immunogen coupling  Host animal 
        
        
P-CBL-1 PAb  clenbuterol  diazotation    rabbit 
P-CBL-2 PAb  clenbuterol  diazotation    rabbit 
P-SBL PAb  salbutamol  no  information  sheep 
P-RCP PAb  ractopamine  bisoxirane    goat 
P-EEO PAb  ethinylestradiol hemisuccinate    goat 
P-HEX PAb  hexestrol  carboxy-propyl-ether  rabbit 
M-CBL MAb  clenbuterol  diazotisation  mouse 
M-TB MAb trenbolone hemisuccinate    mouse 
        
 
aPAb and MAb stand for polyclonal and monoclonal antibody respectively. 
 
Maximum binding capacity 
After immobilisation the maximum binding capacity (Rmax) of the different analyte 
specific chip surfaces was determined by a 20 min long injection of a high 
antibody concentration. For some of the chip surfaces the maximum binding was 
monitored over a longer period to observe surface stability during storage and 
after numerous injections of samples and regeneration solutions (paper I). 
 
Calibration curves and optimisation of assay parameters  
Calibration curves in buffer for CBL, EEO, TB, HEX and RCP were prepared by 
mixing working solutions with concentrations ranging from 0.1 to 100 ng ml
-1 for 
each analyte with the respective antibody (1+1). Inhibition assay standard curves 
were constructed using a 4-parametric fit. To compare the sensitivity of calibration 
curves, the IC50-value, defined as the concentration of the inhibitor (analyte) that is 
required to reduce the response to 50% of b0, was used. Maximum response (b0) 
was defined as the signal in biosensor resonance units (RU) for an antibody 
solution in the absence of analyte under assay conditions. The effect of antibody 
concentration on assay sensitivity was investigated for antibodies P-CBL-1,   
P-CBL-2, M-CBL and P-SBL respectively. The relation between response of 
antibody with a CBL-concentration of 0.5 ng ml
-1 and in absence of CBL and for 
six dilutions per antibody was used for evaluation (more details in paper I). 
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Bovine urine and hair samples 
Twenty lyophilised reference blank bovine urine samples from the EC Reference 
Laboratory in Bilthoven (RIVM) were used in paper II and IV. These samples 
were taken from a broad range of animals including veal calves, fattening bulls, 
heifers, pregnant cows and mature bulls (Sterk et al. 1998). Additional samples 
were collected within the Swedish national control programme. Incurred urine 
samples (clenbuterol and salbutamol) were obtained from TNO Voeding (Zeist, 
the Netherlands). Clenbuterol samples were produced according to Haughey et al. 
(2001) and salbutamol incurred samples according to Elliott et al. (1998b).   
All urine samples were stored at –20 °C until analysis. Results by Haasnoot, 
Kemmers-Voncken & Samson (2002) indicate that urine samples incurred with  
ß-agonists are stable at –20 °C for several years.   
 
A number of blind coded GC-MS negative and GC-MS positive bovine hair 
samples (paper III), were obtained from Veterinary Science Division, Queens 
University of Belfast, UK. Hair samples were stored at room temperature. 
 
Study of sample matrix effects  
Non-specific binding (NSB) from urine and serum to a clenbuterol sensor chip 
surface was measured through injections of samples mixed with double strength 
assay buffer (1+1) without antibody present. The effect of dextran addition   
(1 mg ml
-1 sample) and ultrafiltration (UF) of samples was tested. UF was done as 
follows: 500 µl sample (urine or serum) was added to a 10 kD cut-off filter device 
and spun for 30 min at 14 000 x g (paper II). 
 
The effect of assay buffer composition on non-specific binding (NSB) and 
matrix interferences with the antibody-antigen interaction were studied in a full 
factorial design experiment using the clenbuterol assay as a model. In total, 13 
different buffer compositions were used as further described in paper II.   
Three levels of pH (6, 8 and 10), two levels of NaCl (0.02 and 0.5 M) and two 
levels of HEPES-buffer (10 and 100 mM) were used. For each buffer composition,  
8 samples (Table 2) were injected in triplicate, to describe the most important 
assay parameters.  
 
To represent the maximum sample variation, one dark concentrated urine pool 
(urine A) and one light urine pool (urine B) were prepared from aliquots of RIVM 
blank reference standard urine samples. The two urine pools were divided into 
three aliquots each, pH-adjusted to pH 6, 8 and 10, respectively, and stored frozen 
in small portions until analysis. The statistical software Minitab 12.22 was used 
for evaluation of results by response surface regression and ANOVA analysis with 
a significance level of p < 0.05 (see paper II for more details). 
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Table 2. Summary of the primary response variables used in the buffer optimisation 
experiment. For each buffer composition (n = 13), 8 different samples were injected in 
triplicate. Reagent (Ab or buffer) was mixed (1+1) with blank or spiked matrix (water or 
urine). The specified clenbuterol concentration is in matrix.   
 
          
Sample name  Sample composition Description 
          
          
 Reagent  Matrix  Clenbuterol 
(ng ml
-1) 
 
          
          
Max   Ab
1  H2O  0  Max Ab-response in buffer 
Spike   Ab  H2O  5  Spike in buffer 
NSB A  buffer  urine A
2  0  Non-specific binding for dark 
urine 
NSB B  buffer  urine B
3  0  Non-specific binding for light 
urine 
MaxA   Ab  urine A  0  Max response in dark urine 
MaxB   Ab  urine B  0  Max response in light urine 
SpikeA   Ab  urine A  5  Spike in dark urine 
SpikeB   Ab  urineB  5  Spike in light urine 
          
 
1Ab is monoclonal clenbuterol antibody (M-CBL) at a final dilution of 1/10 000. 
2urine A is dark urine pool.  
3urine B is light urine pool. 
 
Interference from urine with the antigen-antibody interaction at different 
antibody dilutions was studied through analysis of blank and spiked urine using a 
monoclonal clenbuterol antibody (M-CBL). The effect of sample dilution   
(dilution factors from 1 to 32) on background from urine was studied at two 
antibody dilutions. More details can be found in paper II. 
 
Sample preparation 
In paper III, a biosensor assay for analysis of clenbuterol in bovine hair was 
presented. Hair samples were washed with deionised water and ethanol, after 
which they were dried under vacuum at room temperature. The dried hair was cut 
in 1 cm pieces and 200 mg of hair were extracted with 2.5 ml 100 mM NaOH in 
water bath at 100 ºC for 30 min. The extracts were purified by microscale 
centrifuge ultrafiltration with a cut-off of 3 kD (120 min, 14 000 x g) prior to 
biosensor analysis. See paper III for further details. 
 
Urine, adjusted to pH 8.2 ± 0.2, was pre-filtered through a 10 kD cut-off filter 
device by centrifugation for 30 minutes. An aliquot of the urine filtrate was mixed 
(1+1) with antiserum diluted in double strength assay buffer and centrifuged in a 
30 kD cut-off filter device for 12 min. After a filter wash, the retained antibodies 
were collected by placing the filter cup upside down in a clean tube and 
centrifuged at 1200 g for 3 min. The isolate was diluted to original volume with 
assay buffer before biosensor analysis. (paper IV). The principle of integrated 
immunofiltration (IIF) is shown in Figure 11. 
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Figure 11. The principle of integrated immunofiltration (IIF). The sample is mixed with 
antibodies and centrifuged in an ultra-filtration device with a molecular cut-off of 30 kD. 
The filter cup with the retained antibody-antigen complex is turned upside down in a new 
tube, and after a quick spin followed by addition of assay buffer, the complex is directly 
analysed in the biosensor. 
 
Assay validation 
According to Council Directive 2002/657/EC (EC, 2002), the only performance 
criteria specified for screening methods is to have a false negative rate (ß-error)  
of ≤ 5%. The lowest concentration at which this is fulfilled is termed the detection 
capability (CCß). For practical reasons, the false positive rate (α-error) also has to 
be estimated. In the EC Directive, the limit of detection (LOD) has been 
substituted by the decision limit (CCα), which can be calculated as the mean for 
20 blank samples + 2.33 SD. This corresponds to a false positive rate (α-error)  
of 1%. 
 
GC-MS analysis 
GC-MS analysis of hair samples in paper III was performed at Veterinary Science 
Division in Belfast, UK (Elliott, 1995) and GC-MS analysis of urine samples in 
paper IV was performed at the National Food Administration, Uppsala, using a 
method derived from van Ginkel, Stephany & van Rossum (1992).   33
Results and discussion 
 
Sensor chip preparation and assay construction for immuno-
biosensor determination of ß-agonists and hormones (paper I) 
Analyte specific chip surfaces for clenbuterol (CBL), ractopamine (RCP), 
trenbolone (TB), hexestrol (HEX) and ethinylestradiol (EEO) were prepared and 
surface performance in terms of stability, binding capacity and calibration curve 
sensitivity was evaluated and optimised with various antibody reagents. In initial 
immobilisation experiments diazotised CBL was injected over the chip surface in 
the Biacore instrument, but due to contamination of the liquid flow system, all 
subsequent immobilisations were done outside the instrument by manually 
applying the reagents onto the chip. 
 
Stable analyte specific surfaces could be prepared by employing more or less 
modified standard procedures for hapten synthesis used in antibody production 
(Table 1). While immunisation conjugates are designed to act in a chemically   
non-aggressive environment, the immobilised surface has to withstand repeated 
injections of acids, bases or other disrupting solutions needed for regeneration of 
the ligand surface. Hemisuccinate conjugates were consequently avoided since the 
ester-bonds formed are susceptible to both alkaline and acid hydrolysis. 
 
Maximum binding capacities (Rmax), were around 10 000 RU or higher for most 
of the chip surfaces shown in Table 3, with the exception of the diazo-CBL and 
the HEX chip. The lower binding capacities of these surfaces were probably due 
to low recoveries of the non-optimised derivatisation reactions prior to 
immobilisation.  
 
Typical calibration curves for five analytes in buffer are shown in Figure 12. 
Sensor chips for CBL, EEO and TB in combination with antibodies developed for 
conventional immunoassay, such as ELISA and RIA, produced assays with IC50 
values around 0.5 ng ml
-1 (Table 3). The sensitivity of these new biosensor 
inhibition assays compares well with current immunoassays, e.g. IC50 values 
between 0.4 and 2.4 ng ml
-1 were demonstrated for a wide range of commercial 
ELISA kits for clenbuterol (Hahnau & Jülicher, 1996). Immobilisation of RCP and 
HEX will however need further optimisation. The RCP calibration curve was 
sensitive, but levelled out at 60% of b0, while the HEX calibration curve had an 
IC50 value of 12 ng ml
-1. 
 
The same epoxide reaction and linker (bisoxirane, BIS) was used for both 
antibody production (Elliott et al, 1998b) and surface immobilisation of RCP, 
while different reactions were used for HEX. During conjugate formation, 
unwanted epoxide dimers (BIS-RCP-BIS and BIS-HEX-BIS) were formed and 
immobilised on the chip surface. It is likely that RCP antibodies cross-reacted with 
these dimers, which affected the calibration curve. No such effect was seen for 
HEX, which could be taken as an indication of the advantage of using a 
complementary immobilisation strategy. Optimisation of ligand/BIS ratios during 
conjugate formation might both improve the calibration curve for the RCP surface 
and increase the surface capacity for HEX.   34
Table 3. Maximum binding capacity (Rmax) and maximum response (b0) during assay 
conditions for different analyte specific surfaces. Rmax values are generally averages for the 
four flow cells of each chip and IC50 values were calculated from standard curves with 
antibodies of dilutions and active antibody concentrations [Ab] indicated in the Table. 
Antibody dilutions for Rmax determinations ranged from 1/40 to 1/200. 
 
             
      Assay     
             
               
Ligand Immobilisation   
reagent 
Ab Max  binding
1 
Rmax (RU) 
b0
2  
(RU) 
IC50
3 
(ng ml
-1) 
[Ab]
5 
(nM) 
Ab dil. 
               
               
CBL Diazotation  P-CBL-1 1  500  200 2.1  3.8  1/2000 
CBL Thiophosgene  P-CBl-1 13  000  205 1.8  1.5  1/5000 
CBL Thiophosgene  M-CBL  13  000  145 0.45  1.1  1/40000
EEO Carboxy-
methyl-oxime 
P-EEO 10  000  85 0.35  0.7  1/20000
TB Succinimidyl-
carbonate  
M-TB 9  000  72  0.25  0.7  1/40000
RCP Bisoxirane  P-RCP  10  000  412 0.35
4 4.0  1/400 
HEX Bisoxirane  P-HEX  1  500  347 12  3.5  1/400 
               
 
1Maximum binding capacity (Rmax), 20 min injection (flow rate 5 µl min
-1). 
2Maximum assay response (b0), 2 min injection (flow rate 30 µl min
-1). 
3The IC50 was defined as the concentration of the inhibitor (analyte) required to reduce the 
signal in RU to half the signal measured with no inhibitor present (b0). 
4The IC50 value for RCP was calculated from the dynamic range of the curve  (fig. 12)  
5The concentration [Ab] refers to active antibody concentration as described earlier. 
 
 
 
 
 
 
Figure 12. Buffer calibration curves from analyte specific surfaces of clenbuterol (CBL), 
ethinylestradiol (EEO), trenbolone (TB), ractopamine (RCP) and hexestrol (HEX). All 
calibration curves were normalised against b0 for each substance respectively. Data for 
assay response, and IC50 values for standard curves, are presented in Table 3. For the   
CBL-curve, the thiophosgene chip was used.  
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In general, the prepared surfaces were stable during storage and prolonged use. 
The thiocyanate clenbuterol chip was used for over 5000 sample injections over a 
three-year period. Despite a response decrease of about 20% for a 1 nM antibody 
concentration the precision remained constant.  
 
The running buffer used had a pH of 8.2 and a NaCl concentration of 500 mM 
compared to pH 7.4 and 150 mM NaCl in standard HBS-EP buffer (Biacore AB). 
The higher NaCl content was used to reduce non-specific binding of proteins to 
the chip surface, and the pH to operate at the response maximum of the antibody. 
There was no non-specific binding (NSB) from the two monoclonal antibodies 
used, while the polyclonal sera gave a constant non-specific binding of 5-10% of 
the total antibody response over the whole range of dilutions investigated. 
 
Regeneration conditions required for complete regeneration of the chip surface 
were generally found to be harsher than the conditions for elution of analyte from 
affinity columns suggested by Tsang & Wilkins (1991). All antibodies tested were 
totally regenerated with a pulse of 100 mM NaOH with 20% acetonitrile.   
An alternative with less baseline disturbance was a two step regeneration with a  
6 M guanidine-HCl solution at pH 1.5, followed by a pulse of 100 mM NaOH. 
 
In the Biacore system flow rates of 1-100 µl min
-1 can be used. A flow rate of  
30 µl min
-1 was chosen for the current assays due to maximum sensitivity and 
acceptable antibody consumption. It was found that an increase of flow rate from 
10 to 30 µl min
-1 resulted in an increase of standard curve sensitivity with 
approximately a factor 2 or more, while a further increase of the flow up to a 100 
µl min
-1 had no additional effect. In a study by Gaudin & Pavy (1999) an increase 
in flow rate from 5 to 20 µl min
-1 decreased the IC50 value with a factor of 5 in 
buffer for their sulfamethazine assay. In milk however no such effect was 
observed. 
 
Serial dilution of four antibodies spiked with CBL (0.5 ng ml
-1) indicated that it 
was not possible to dilute three of them enough to fully benefit from their high 
avidities due to the response/noise ratio, i.e. mass sensitivity limitations of the 
SPR-instrument, as further discussed in paper I. 
 
One way to increase the response would be to enhance the signal by injecting a 
secondary antibody after the first sample injection. It was possible to enhance the 
signal from P-CBL-1 by 4-5 times through a subsequent injection of an affinity 
purified goat-anti-rabbit IgG antibody. The benefit was however limited by   
non-specific binding from the secondary antibody to the surface of about 15 RU. 
At the high concentration end of the standard curve the response from the primary 
antibody went down to and below the response for non-specific binding from the 
secondary antibody, causing increased variability between injections. Further 
work on the control of non-specific binding is needed if secondary antibodies are 
to be useful for improving assay sensitivity. 
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Matrix effects in immunobiosensor determination of clenbuterol 
in urine and serum (paper II) 
The ß-agonist assay was applied as a model to study matrix effects from urine and 
serum in residue analysis. Interferences with the antigen-antibody interaction, and 
non-specific binding (NSB) of matrix components to the sensor surface, were 
systematically studied. A full factorial design experiment was employed for 
evaluating the effects of assay buffer composition. The experiment showed that it 
was possible to run the assay at pH 8-10, using NaCl concentrations between 20 
and 500 mM, and HEPES buffer concentrations between 10 and 100 mM, while 
pH 6 was less suitable due to major NSB from both urine samples and antibody.  
 
For blood serum, ultrafiltration (UF) efficiently eliminated an otherwise high 
NSB of proteins to the sensor chip. NSB was also seen to varying degrees for 
urine, although to a much lesser extent than for serum. Using an assay buffer at pH 
10 in combination with high salt concentration eliminated NSB for the vast 
majority of urine samples, while ultrafiltration was needed at pH 8. Addition of 
soluble dextran to the assay buffer reduced the NSB to some extent for serum, but 
had no effect on urine. 
 
The urine matrix produced a substantial inhibition of the binding of antibodies 
to the sensor surface immobilised antigen in all the assays for ß-agonists and 
hormones developed in paper I. The inhibition from serum was smaller compared 
to urine, as shown for clenbuterol in Figure 13. Furthermore, the variation 
between individual samples analysed separately was considerably higher for urine  
(CV values for urine were approximately 35% compared to 1% for serum and 
buffer). Background correction, e.g. by using calibration curves made up in 
matrix, would therefore not be an efficient way of improving the assay for urine. 
 
 
 
Figure 13. Clenbuterol calibration curves in buffer, bovine serum and urine. A polyclonal 
antibody (P-CBL-1) diluted 1/2000, corresponding to an active antibody concentration of 
3.8 nM, was used. All results were normalised against max response in buffer (b0) and 
expressed as relative response (% of b0).   37
In addition to NSB, the buffer optimisation experiment was designed to study 
effects of the running buffer composition on the antigen-antibody interaction.   
Dark and light urine were used to represent the maximum sample variation, and 
clenbuterol spikes in both buffer and urine were analysed for each buffer 
combination according to Table 2. In urine small or no statistically significant 
systematic effects from the studied buffer composition parameters could be found, 
although a significant response optimum for the maximum response in buffer 
(“Max”) was obtained at pH 8 with 500 nM NaCl. However, neither the inhibition 
effect from urine (as illustrated in Figure 13), nor the difference in response 
between dark and light urine pools, were substantially affected by buffer 
composition.  
 
As expected, assay sensitivity increased markedly with higher antibody dilution 
in both buffer and urine, as seen by the steep slopes of the relative response plots 
for clenbuterol in Figure 14. In comparison, the background from urine matrix was 
close to constant. Background, expressed as concentration, decreased with higher 
antibody dilution, e.g. from 3.0 to 1.0 ng ml
-1, when antibody dilution was 
increased from 1/10 000 to 1/40 000. Sample dilution is commonly applied in fast 
assays (Sternesjö, Mellgren & Björck, 1995; Baxter et al., 1999) to reduce sample 
matrix background. In the current assay, background values for urine did instead 
increase with increased sample dilution as further discussed in paper II.   
In conclusion, dilution of the antibody increased the sensitivity of the assay and 
reduced urine background, while sample dilution had the opposite effect on the 
urine background.  
 
 
 
Figure 14. The effect of antibody dilution on background from urine. Antibody dilutions 
from 1/2000 to 1/40 000 corresponding to active antibody concentrations of 16 to 0.8 nM 
were used. Blank urine diluted 5 times (a), blank urine diluted 5 times and spiked with 
clenbuterol at 3 ng ml
-1 (b) and clenbuterol (3 ng ml
-1) standard in water (c) were mixed 
(1+1) with the respective antibody dilution. All results were normalised against max 
response in buffer (b0) for the respective antibody dilution and expressed as relative 
response (% of b0).   38
Analysis of clenbuterol in bovine hair (paper III) 
The aim was to explore the possibility of using an SPR-biosensor for fast 
screening analysis of clenbuterol in hair with a minimum of sample preparation. 
To validate the assay, a number of hair samples from animals treated with 
clenbuterol were analysed, and the results were compared with results from   
GC-MS analysis.  
 
A fast extraction method using 100 mM NaOH was developed. Higher 
concentrations of NaOH were tested, but dissolved the hair completely, which 
increased the background for blank sample extracts markedly. Compared to the 
carbonate buffer extraction developed by Elliott, Crooks & McCaughey (1995),  
the recovery of clenbuterol from incurred samples was higher with the new 
extraction method. Non-specific binding (NSB) of about 400 RU from the hair 
extracts was reduced down to 5-50 RU by ultrafiltration. 
 
Results were evaluated with and without enhancement as indicated in Figure 15. 
The sample was mixed with primary antibody (1+1) and injected, followed by a 
subsequent injection of a secondary antibody, enhancing the signal from the 
primary antibody about three times both in buffer and hair extract. Buffer and hair 
extract curves were of similar shape, but the maximum response (b0) in hair 
extract was approximately 10 % lower than in buffer. The maximum response (b0) 
of the standard curve was about 500 RU, and the dynamic range of the standard 
curve was about 0.4 to 14 ng ml
-1, corresponding to 10 and 350 ng g
-1 hair. With a 
higher antibody dilution lower concentrations could be detected, but the lower 
antibody-specific biosensor response would increase the risk for false negative 
results due to NSB from samples. 
 
 
Figure 15. Overlay plot of 3 sensorgrams from injections of blank hair extracts spiked with 
clenbuterol. The concentrations are (a) 30 (b) 5 and (c) 0.2 ng ml
-1 corresponding to 375, 
62.5 and 2.5 ng g
–1 hair, respectively. Recorded response values (RU) from primary and 
secondary antibody injections are indicated with arrows (a-c) and (d-f) respectively.   39
Detection limits (mean + 3SD) for the assay, calculated from seventeen GC-MS 
negative hair samples, were 10 ng g
-1, for hair with enhancement, and 15 ng g
-1,  
for hair without enhancement. The lower detection limit for enhancement is 
probably due to the fact that the secondary antibody injection is less influenced by  
non-specific binding from the hair matrix  
 
Results from biosensor analysis of GC-MS positive hair samples are shown in 
Figure 16. The correlation between the BIA-method with enhancement and the 
GC-MS-method was 92.7% (R
2). Concentrations found with the biosensor method 
were generally lower than results from GC-MS analysis, which was probably due 
to lower extraction recovery for the new simplified extraction procedure 
developed for the BIA method. It is likely that a more rigorous solubilization of 
the hair tissue is needed for complete recovery from hair of drug treated animals. 
In the lower concentration range (up to 100 ng g
-1 hair), the BIA results were on 
the average 71 % of those obtained by GC-MS. 
 
The sample capacity of the current method is approximately 48 samples a day. 
The detection limit of the new assay is comparable to other screening methods, 
reporting LOD values in the range 0.3 - 22 ng g
-1 (Gleixner, Sauerwein & Meyer, 
1996; Haasnoot et. al., 1998; Appelgren et al., 1996; Elliott, Crooks & 
McCaughey, 1995; Godfrey et al., 1996). In contrast to most of the published 
methods in the area, no organic solvent or solid phase extraction step was needed. 
 
 
 
 
Figure 16. Clenbuterol concentrations obtained with the new biosensor method in 
comparison with results from the GC-MS method in hair from clenbuterol treated animals 
(n=22).  
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Immunobiosensor determination of ß-agonists in urine using 
integrated immunofiltration clean-up (paper IV) 
A fast immunobiosensor method for screening of ß-agonists in urine using 
integrated immunofiltration (IIF) clean-up is described. The aim was to develop a 
fast clean-up method suitable for analysis of both CBL and SBL type of ß-agonists 
without the use of organic solvents. Two antibodies with different   
cross-reactivities for clenbuterol and salbutamol were used to study optimal 
conditions for IIF.  
 
In IIF the sample is mixed with antibody in an ultra-filtration device (cut off  
30 kD) and after a short incubation and centrifugation the filter is washed with 
buffer. The antibodies trapped on the filter are recovered and the unliganded 
fraction is detected directly in the biosensor immunoassay with clenbuterol 
immobilised on the sensor surface. The principles of IIF clean-up are further 
described in Figure 12. 
 
A final antibody dilution of 1/40 000 (equivalent to an active antibody 
concentration of 0.85 and 1.1 nM for M-CBL and P-SBL respectively) was used 
to obtain a working range of 0.2 to 5 ng
-1 ml urine. Since the same antibody 
aliquot is used for clean-up and biosensor analysis, the capturing capacity of 
analyte in the clean-up step is limited by the degree of antibody dilution required 
to get a calibration curve with the chosen working range in the biosensor assay. 
Thus, by increasing the antibody concentration, more analyte can be recovered 
during IIF but the assay sensitivity is at the same time decreased.  
 
Direct and IIF calibration curves for clenbuterol and salbutamol in the buffer 
and urine pools for two different antibodies are shown in Figure 17. IIF-curves for 
both antibodies were somewhat more flat than the corresponding “external” CBL 
or SBL standard buffer curve, indicating increased loss of analyte at higher 
concentrations. A higher loss at high analyte concentrations is explained by the 
limited capturing capacity discussed above. IIF-curves in buffer were generally 
more sensitive than the corresponding urine curves, indicating additional loss of 
analyte due to interference from urine on the antibody-antigen interaction.  
 
There were however some differences between the two antibodies during IIF. 
As seen in Figure 17a, IIF clean-up caused relatively small losses of CBL in buffer 
and urine when the monoclonal antibody M-CBL was used. Corresponding   
IIF-curves for SBL in urine and buffer were however much less sensitive, 
levelling out at 80% and 65% binding respectively. Thus, IIF with this antibody  
gave a clean-up procedure with a rather high selectivity for clenbuterol. 
 
By comparison, the IIF-curves for the polyclonal P-SBL were much more 
similar (Figure 17b). There was no or very little difference between the two   
ß-agonists, although the cross-reactivity rate of the antibody measured direct in 
buffer in the instrument was 131% for SBL as compared to CBL. The two buffer 
curves were somewhat more sensitive than the corresponding urine curves, but an 
analyte concentration of 10 ng
-1 ml gave an inhibition down to about 50% for 
both. Since the aim was to develop an assay capable of detecting several   
ß-agonists, the P-SBL antibody was chosen over the M-CBL for further studies. 
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Figure 17. Clenbuterol (CBL) and salbutamol (SBL) calibration curves direct in buffer 
(External buffer) and after sample clean-up with integrated immunofiltration (IIF) in buffer 
(IIF-buffer) and urine pool (IIF-urine) for a) antibody M-CBL and b) antibody P-SBL, 
respectively. All concentrations are in final solution (for concentrations in urine multiply by 
dilution factor 2). 
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From the results above, it is obvious that quantitative measurements would 
require the use of an IIF calibration curve in urine. However, if the intended use of 
the method is screening of high numbers of samples for the presence of banned 
compounds only, quantitation is not needed. In order to maximise the sample 
capacity the calibration curve can therefore be excluded or be exchanged for a 
direct “external” buffer standard curve when the assay is used in routine control. 
 
To validate the assay, 20 reference bovine urine samples were analysed blank 
and spiked with 1 ng ml
-1 of clenbuterol. The good result of IIF clean-up on 
sample-to-sample variation and overall sample matrix background is illustrated in 
Figure 18. Response values for IIF-treated versus untreated urine increased from 
60 ± 17.1% to 91.2 ± 3.5% of b0 resulting in a decision limit CCα (mean of 
blanks - 2.33 SD) of 83.0 %, corresponding to 0.29 ng ml
-1 in urine. In conclusion, 
it was possible to use a decision limit corresponding to a false positive rate as low 
as 1% (α-error), while at the same time having a false negative rate (ß-error) of  
< 1% at the 1 ng ml
-1 level. Since the EU-directive (EC, 2002) requires the ß-error 
to be ≤ 5% for screening methods, the CCß of the assay is well below 1 ng ml
-1. 
 
During 2002 and 2003, a total of 348 individual bovine urine samples were 
screened at the 1 ng ml
-1 level within the Swedish national residues control 
programme. None of these samples tested positive. In addition, eight urine 
samples incurred with clenbuterol, and one with salbutamol were analysed. The 
concentrations of the CBL-incurred samples determined with GC-MS were 0.17, 
0.72, 1.0, 1.2, 1.8, 3.5, 5.2 and 14 ng ml
-1 respectively, while the SBL sample had 
a concentration of 1.0 ng ml
-1. Using CCα as the cut-off gave only one false 
negative sample (0.17 ng ml
-1). Results from these incurred samples, and samples 
spiked at concentrations of 1 and 0.5 ng ml
-1 respectively, indicate that the method 
is able to detect salbutamol at 0.5 ng ml
-1, and clenbuterol, brombuterol and 
mabuterol at somewhere between 0.5 and 1 ng ml
-1, as further discussed in paper 
IV. The sample throughput capacity was at least 48 samples per person and 
working day. 
 
 
 
Figure 18. Relative response values expressed as % of b0 obtained from 20 reference blank 
bovine urine samples using the P-SBL antibody for (a) direct BIA analysis of undiluted 
samples and (b) after integrated immunofiltration (IIF).    43
Conclusions and future research 
 
This thesis shows that the immunobiosensor can be applied for fast and sensitive 
detection screening analysis for various illegal drugs. Sensor chip surfaces, 
prepared by more or less modified standard procedures for hapten synthesis, 
resulted in assays with IC50 values of around 0.5 ng ml
-1 for clenbuterol, 
ethinylestradiol and trenbolone.  
 
Routine assays for clenbuterol in bovine hair and urine were developed and 
validated. For hair, a sandwich assay format was used. A rapid and simple 
extraction procedure using 100 mM NaOH was developed, and the assay was 
validated by analysis of hair samples from animals treated with clenbuterol. The 
critical factor for assay sensitivity was non-specific binding to the sensor chip 
surface from hair extracts, which was controlled by ultrafiltration of samples and a 
secondary antibody. The LOD of the hair assay was 10 ng ml
-1.  
 
For the urine assay, a novel clean-up procedure using integrated 
immunofiltration was developed. The clean-up efficiently reduced urine matrix 
disturbances from non-specific binding to the surface and interference with the 
antigen-antibody interaction. The new procedure enabled detection of several   
ß-agonists, including clenbuterol, salbutamol, mabuterol and brombuterol, at 
concentrations below 1 ng ml
-1. At least 48 samples could be processed and 
analysed by one person in one working day.  
 
The major limiting factor for biosensor analysis of residues is interference from 
the sample matrix. To date, sample clean-up is still needed for most biosensor 
methods developed for residue analysis. A future goal would be to develop     
assays with no need for sample clean-up. Improvements of assay sensitivity might 
also be needed to meet future regulatory requirements. The use of receptors or 
genetically designed binding biomolecules, possibly in combination with multi-
spot or multi-channel instruments, would enable high sample throughput and multi 
analyte detection. Another intriguing possibility of receptor-based assays is that 
the response may be directly linked to a specific biological, i.e. toxic, effect. 
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